Because of the reported activity of the lipid-soluble nitrosoureas in non-small cell carcinoma of the lung, a phase II trial of chlorozotocin in this disease was undertaken. Thirty-five patients were enlisted in the study between March 1977 and March 1978. Two PRs were noted in the 30 (7%) evaluable patients. At 95% confidence limits, the predicted true response rate is 2%-18%. The authors conclude that chlorozotocin, when given in the present dose and schedule, is only a marginally effective agent in the treatment of non-small cell carcinoma of the lung, and that it offers no therapeutic advantage over the nitrosoureas currently used in the treatment of this disease.
|Original language||English (US)|
|Number of pages||2|
|Journal||Cancer Treatment Reports|
|Publication status||Published - Dec 1 1979|
ASJC Scopus subject areas
- Cancer Research